TempraMed Signs Exclusive Distribution Agreement with SPORTORO for Croatia, Serbia and Bosnia and Herzegovina

(CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) TempraMed Technologies Ltd. announced that its subsidiary, TempraMed Israel Ltd., has signed a definitive exclusive distribution agreement with SPORTORO d.o.o., a Croatian company headquartered in Osijek, for the commercialization of TempraMed products in Croatia, Serbia, and Bosnia and Herzegovina. The agreement, dated October 19, 2026, establishes an initial 36-month exclusive distribution framework covering VIVI Cap™, VIVI Epi™, and VIVI Med™. SPORTORO is responsible for developing commercial activities and obtaining all necessary country-specific governmental licenses and regulatory approvals at its own expense. The exclusivity of the agreement is subject to performance and other conditions as outlined in the agreement. The agreement sets annual minimum purchase targets valued at approximately US$550,000 over the 36-month initial term, assuming an all-VIVI Cap product mix at current pricing. First-year operational targets include an initial order to be placed and paid in full upon execution, with a subsequent order targeted within six months of the initial order. The agreement includes structured sales and marketing planning, distributor-funded market development, and conditional TempraMed launch support, with provisions for subsequent renewals subject to performance and mutual agreement. In Croatia, the Croatian Institute of Public Health reports 406,341 registered people with diabetes in 2025. The International Diabetes Federation estimates approximately 718,500 adults living with diabetes in Serbia and 316,400 in Bosnia and Herzegovina in 2024. The World Health Organization reports age-standardized adult obesity prevalence of 29.5% in Croatia in 2022. SPORTORO d.o.o. is a privately held Croatian company established in 2018 and led by director Mario Festetics de Tolna. Under the agreement, SPORTORO intends to extend its commercial activities into personal medication temperature protection and develop the necessary sales, marketing, and regulatory channels across Croatia, Serbia, and Bosnia and Herzegovina. Ron Nagar, Founder and Chief Executive Officer of TempraMed, stated that the agreement extends TempraMed's international distribution strategy into three additional Southeast European markets through a single commercial relationship. The agreement is structured with measurable purchase targets and a planned market-development program. TempraMed's commercial portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™.

TempraMed Granted Mexican Patent for Newest Product, VIVI Box

(CSE:VIVI) (FSE:9DY) TempraMed Technologies Ltd. announced that its Mexican patent application No. MX/a/2021/004595 has been formally granted by the Mexican Patent Office. The patent covers key aspects of the company's multi-medication storage box, VIVI Box™, including proprietary thermal-insulation and smart-monitoring architecture. The VIVI Box™ is designed to provide continuous temperature protection during power interruptions or refrigerator temperature fluctuations for several medication devices and vials, portable all-day travel functionality for secure on-the-go cold storage, and smart content tracking with cloud-based data integration. Once launched, VIVI Box™ will add to TempraMed's existing portfolio of four products currently being sold in market. The company has begun exploring commercial application opportunities for the VIVI Box™. CEO Ron Nagar stated that the formal grant of the Mexican patent is a significant milestone in TempraMed's global intellectual property strategy and strengthens the company's position in the Latin American medical device market. Nagar also emphasized the importance of protecting core innovations as TempraMed builds out new product categories and scales its platform. This Mexican patent grant follows recent milestones, including the grant of similar patents in South Korea and China, entry into several distribution agreements, and validation of the company's ROI model for insurance payors, as verified by hundreds of clinicians recommending TempraMed's VIVI Cap to patients. These achievements support TempraMed's multi-year strategy to scale globally, introduce new product categories, and establish itself as a leader in temperature-regulated medication protection and management. TempraMed's current product line includes VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med. The company operates in North America, Europe, and Asia.

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

(CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) TempraMed Technologies Ltd. announced that its VIVI Cap Smart™ platform now supports connectivity with Apple Health and Google Fit. VIVI Cap Smart™ is a connected temperature-protection device for insulin pens, GLP-1 therapies, and other injectable medications, combining passive thermal-shield technology with digital features for monitoring medication exposure, tracking injections, sending reminders, and sharing medication-use data with caregivers and healthcare professionals. The new connectivity is described as a strategic milestone for TempraMed, aligning with trends toward home-based care, wearable devices, AI-enabled health platforms, and patient-generated health data. VIVI Cap Smart is designed to allow patients to include injection-related information alongside broader personal health data in leading health platforms. The platform captures injection activity, medication reminders, temperature exposure, and adherence-related signals from insulin, GLP-1, and other injectable medication use. It is intended to support home-care and remote monitoring models by providing better visibility for patients, family members, caregivers, and healthcare professionals as more chronic therapies move into the home. VIVI Cap Smart is pen-agnostic and platform-ready, designed to work across multiple pen brands and therapy categories while adding temperature protection. TempraMed believes injectable medication data is increasingly relevant to wearable, digital-health, AI, pharma, medical-device, and payer platforms seeking new clinical signals and better patient engagement. The product is built around a connected-device and subscription model, supporting the potential for software-enabled recurring digital-health revenue in addition to hardware sales. Hundreds of millions of patients worldwide use injectable medications for diabetes, weight management, autoimmune conditions, fertility, allergies, and other chronic or acute conditions. VIVI Cap Smart was developed to address the gap in digital-health ecosystems, which often lack data on injectable medication use and temperature exposure. The platform provides temperature protection, automatic injection-event capture, medication reminders, app connectivity, voice dose recognition, manual dose entry, real-time alerts, data analytics, and integration potential for remote patient monitoring and health platforms. Ron Nagar, Chief Executive Officer of TempraMed, stated that VIVI Cap Smart turns injectable medication into a connected data point, offering better reminders and visibility for patients and caregivers, and providing digital-health platforms with a critical clinical signal. The company’s long-term strategy is to make every injection device connected and temperature protected, with a broader smart platform roadmap including connected solutions for insulin pens, GLP-1 therapies, epinephrine auto-injectors, vials, biologics, and multi-medication storage formats. TempraMed’s commercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™.

TempraMed Announces Upsize to Offering

(CSE:VIVI) TempraMed Technologies Ltd. has announced an upsize to its previously disclosed non-brokered private placement, now referred to as the Upsized Offering. The Upsized Offering will consist of up to C$600,000 in unsecured convertible debentures and up to C$1,000,000 in units, for total aggregate gross proceeds of up to C$1,600,000. Each unit will include one common share and one share purchase warrant. Each warrant will entitle the holder to purchase one additional common share at a price of C$1.00 at any time up to 18 months after the closing date of the Upsized Offering. The unsecured convertible debentures will bear interest at a rate of 10% per annum, calculated monthly and payable quarterly in cash. The debentures will mature on the one-year anniversary of their issuance. The principal amount of each debenture may be converted into common shares at a conversion price of $0.50 per share by the holder at any time on or before the maturity date. On the maturity date, holders may convert the outstanding principal and any accrued and unpaid interest into shares at the same conversion price. The intended use of proceeds from the Upsized Offering is to fund new inventory, product development, scaling of the sales and marketing division globally, and for general working capital. All securities issued in connection with the Upsized Offering will be subject to a statutory hold period of four months and one day following issuance, in accordance with Canadian securities laws. The Upsized Offering is subject to approval by the CSE and the filing of all required documentation. The securities have not been and will not be registered under the United States Securities Act of 1933 or any state securities laws, and may not be offered or sold within the United States unless registered or exempt from registration.

TempraMed Announces Extension of Maccabi Healthcare Services Agreement

(CSE: VIVI) (OTCQB: TMPTF) TempraMed Technologies Ltd. announced that Maccabi Healthcare Services has exercised its option to extend its agreement with TempraMed for an additional year under the same terms. Maccabi serves more than 2.6 million members, representing a significant portion of Israel's population. TempraMed's product portfolio is currently available through Maccabi's healthcare network, providing members with access to the Company's patented temperature-protection technology for injectable medication, like Insulin, GLP-1, and peptides. TempraMed has sold approximately 150,000 devices globally and has established relationships with major healthcare and distribution organizations as part of its strategy to expand access to its medication protection platform. Nancy Goertzen has resigned from the Company's Board of Directors and from all Board committees on which she served, effective August 19, 2026.

TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies

(CSE: VIVI) (OTCQB: TMPTF) TempraMed Technologies Ltd. has entered into a definitive exclusive distribution agreement with TEM Consulting International S.A. for the distribution and commercialization of TempraMed's portfolio in Panama. The agreement transitions the previously announced Letter of Intent between TempraMed and TEM into a definitive commercial relationship. TEM will serve as TempraMed's exclusive distributor in Panama and is now advancing distribution of the Company's products into clinics and pharmacies. TempraMed has fulfilled its first bulk commercial order for distribution into clinics and pharmacies. TempraMed's portfolio addresses a growing range of injectable and temperature-sensitive medications. TEM Consulting International S.A. has established itself since 2014 as a premier Panamanian specialist in the import and distribution of high-quality surgical and medical disposables. TempraMed has operations in North America, Europe, and Asia.

TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness

(CSE: VIVI) TempraMed Technologies Ltd. announced a strategic partnership with Stealth Health, a leading telemedicine platform for longevity and precision wellness in North America. The agreement integrates TempraMed's VIVI product portfolio into Stealth Health's ecosystem of direct-to-patient care and enterprise white-label telemedicine services, creating a new distribution channel for medication protection products across North America. Stealth Health is fully operational across all 50 U.S. states since January 2026 and serves patients prescribed temperature-sensitive medications including hormones, peptides, and biologics. TempraMed's patented, battery-free thermal insulation technology is engineered from space-grade materials and is FDA-registered. The partnership supports TempraMed's commercialization strategy to build scalable adoption through clinical and wellness channels and provides access to a B2C platform and patient population. TempraMed operates in North America, Europe, and Asia, and the partnership opens new global distribution potential through Stealth Health's expanding white-label network. The company projects that the partnership will generate patient and distribution demand and anticipates growth of Stealth Health's white-label platform relevant to TempraMed's global distribution ambitions.

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

(CSE: VIVI) TempraMed Technologies Ltd. announced the expansion of its relationship with McKesson Medical-Surgical through an agreement dated June 23, 2026, broadening collaboration to include full portfolio distribution across North America. The partnership enables distribution of all TempraMed products, including VIVI Cap®, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™, across the MMS sales and distribution network and through Simply Medical, LLC, B2B2C partners, and platforms such as Optum Now. McKesson Medical-Surgical's marketplace aggregates approximately 270,000 SKUs and serves a nationwide customer base in the United States. The agreement provides TempraMed with immediate access to a highly diversified and recurring customer base across non-acute care settings, including physician offices, ambulatory surgery centers, long-term care facilities, and home health organizations. The company projects that the inclusion of its full product portfolio across McKesson Medical-Surgical's network is expected to enhance product visibility, streamline procurement, and accelerate adoption of its proprietary thermal protection solutions. TempraMed's transition toward a more diversified revenue model is complemented by scalable B2B distribution channels. The agreement is non-exclusive and aligns with industry trends toward decentralized care delivery.

TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia

(CSE: VIVI) TempraMed Technologies Ltd. announced it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company for exclusive distribution of TempraMed products in the Kingdom of Saudi Arabia. The LOI provides for a 5-year distribution arrangement within Saudi Arabia, with exclusivity requiring minimum purchase orders from Rawafed of approximately US$3.1 million over the 5-year period. Under the LOI, exclusivity would become effective following successful regulatory approval by the Saudi Food and Drug Authority and placement of the first commercial order of at least US$170,000. The International Diabetes Federation reports that Saudi Arabia had approximately 5.34 million adults with diabetes in 2024, representing 23.1% adult prevalence, and projects the number of adults with diabetes in Saudi Arabia could reach approximately 9.5 million by 2050. Grand View Research estimates Saudi Arabia's GLP-1 receptor agonist market revenue at USD 348.3 million in 2025 and projects growth to USD 1.248 billion by 2033. The company expects to receive SFDA approval in due course. Rawafed Health International Company is described as having approximately 25 years of experience in the Kingdom's healthcare sector.

TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications

TempraMed Technologies Ltd. (CSE: VIVI), a medical-technology innovator, announced that it is featured on the Dr. Phil Show in a national broadcast episode focused on the risks of temperature exposure for insulin and other injectable medications. The segment, titled "Dose of Reality: The Truth About Temperature. The Risk Is Real.", aims to bring national attention to the challenges faced by millions who rely on temperature sensitive medications. The episode will also be released on YouTube and major podcast platforms on Friday, May 22. TempraMed's feature on the Dr. Phil Show is part of its broader strategy to build awareness around temperature sensitive medication protection and tracking. The company offers a portfolio of patented, FDA registered, thermal insulation devices that work 24/7 without batteries or external power. TempraMed operates in North America, Europe, and Asia, and plans to continue expanding globally. Investors are encouraged to contact the company for more information.

TempraMed Announces Continuance into Ontario

TempraMed Technologies Ltd. (CSE: VIVI) announced that it has continued out of the provincial jurisdiction of British Columbia into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario). Shareholders approved this continuance by special resolution at the Company's special meeting of shareholders held on April 10, 2026. The company has replaced its notice of articles and articles with new articles of continuance and by-laws under the OBCA. The CUSIP / ISIN numbers and stock symbol for the Company's common shares remain unchanged. TempraMed is a global medical device company with a portfolio of temperature-controlled medication storage solutions and operations in North America.